Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model

Dabaghian, Mehran; Latifi, Ali Mohammad; Tebianian, Majid; Najminejad, Hamid; Ebrahimi, Seyyed Mahmoud

doi:10.1016/j.vaccine.2018.02.072

Cited by 42 publications

(28 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mucosal vaccines have some advantages compared with traditionally vaccines, and most infections occur at a mucosal surface or spread from mucosal surfaces [201]. Studies have shown that mucosal administration could provide an early defense against invading pathogens, as the local antibodies of the mucosa work faster than serum antibodies, are higher in level, and have a greater maintenance time [202,203]. The process of immunity is shown in Figure 6 [204].…”

Section: Applications Of Chitosan Derivative Nanoparticles In Mucosalmentioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

586

326

View full text Add to dashboard Cite

Chitosan is a product of the deacetylation of chitin, which is widely found in nature. Chitosan is insoluble in water and most organic solvents, which seriously limits both its application scope and applicable fields. However, chitosan contains active functional groups that are liable to chemical reactions; thus, chitosan derivatives can be obtained through the chemical modification of chitosan. The modification of chitosan has been an important aspect of chitosan research, showing a better solubility, pH-sensitive targeting, an increased number of delivery systems, etc. This review summarizes the modification of chitosan by acylation, carboxylation, alkylation, and quaternization in order to improve the water solubility, pH sensitivity, and the targeting of chitosan derivatives. The applications of chitosan derivatives in the antibacterial, sustained slowly release, targeting, and delivery system fields are also described. Chitosan derivatives will have a large impact and show potential in biomedicine for the development of drugs in future.

show abstract

Section: Applications Of Chitosan Derivative Nanoparticles In Mucosalmentioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

586

326

View full text Add to dashboard Cite

show abstract

“…This observation correlated closely with the reduced lung pathology and the substantial clearance of the virus from the animal lungs. Other polymeric nanoparticles, such as chitosan, a natural polymer composed of randomly distributed β-(1-4)-linked d-glucosamine and N-acetyl-d-glucosamine, and N-(2-hydroxypropyl)methacrylamide/N-isopropylacrylamide (HPMA/NIPAM), were also investigated as intranasal vaccines against respiratory viruses (85)(86)(87)(88)(89)(90)(115)(116)(117)(118)(119)(120)(121). Overall, polymeric nanoparticles have many advantages, including biocompatibility (122), antigen encapsulation and stabilization (123,124), controlled release of antigens and intracellular persistence in APCs (125,126), pathogen-like characteristics, and suitability for intranasal administration (126,127).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Nanoparticle-Based Vaccines Against Respiratory Viruses

et al. 2019

View full text Add to dashboard Cite

The respiratory mucosa is the primary portal of entry for numerous viruses such as the respiratory syncytial virus, the influenza virus and the parainfluenza virus. These pathogens initially infect the upper respiratory tract and then reach the lower respiratory tract, leading to diseases. Vaccination is an affordable way to control the pathogenicity of viruses and constitutes the strategy of choice to fight against infections, including those leading to pulmonary diseases. Conventional vaccines based on live-attenuated pathogens present a risk of reversion to pathogenic virulence while inactivated pathogen vaccines often lead to a weak immune response. Subunit vaccines were developed to overcome these issues. However, these vaccines may suffer from a limited immunogenicity and, in most cases, the protection induced is only partial. A new generation of vaccines based on nanoparticles has shown great potential to address most of the limitations of conventional and subunit vaccines. This is due to recent advances in chemical and biological engineering, which allow the design of nanoparticles with a precise control over the size, shape, functionality and surface properties, leading to enhanced antigen presentation and strong immunogenicity. This short review provides an overview of the advantages associated with the use of nanoparticles as vaccine delivery platforms to immunize against respiratory viruses and highlights relevant examples demonstrating their potential as safe, effective and affordable vaccines.

show abstract

“…In the last decade, a wide variety of nanoparticulate systems have been designed to induce humoral and cellular immunity against various viral infections. Various phospholipidic, polymeric, inorganic, carbon-based, metallic [269][270][271], and protein-based systems [272] have been explored for the development of vaccines [273][274][275][276][277][278]. In addition, the nanoparticles have been surface modified to carry antigens or epitomes to target antigen-presenting cells [279,280].…”

Section: Nanovaccinesmentioning

confidence: 99%

Nanotechnology-based antiviral therapeutics

Chakravarty

Vora

2020

Drug Deliv. and Transl. Res.

197

165

View full text Add to dashboard Cite

The host immune system is highly compromised in case of viral infections and relapses are very common. The capacity of the virus to destroy the host cell by liberating its own DNA or RNA and replicating inside the host cell poses challenges in the development of antiviral therapeutics. In recent years, many new technologies have been explored for diagnosis, prevention, and treatment of viral infections. Nanotechnology has emerged as one of the most promising technologies on account of its ability to deal with viral diseases in an effective manner, addressing the limitations of traditional antiviral medicines. It has not only helped us to overcome problems related to solubility and toxicity of drugs, but also imparted unique properties to drugs, which in turn has increased their potency and selectivity toward viral cells against the host cells. The initial part of the paper focuses on some important proteins of influenza, Ebola, HIV, herpes, Zika, dengue, and corona virus and those of the host cells important for their entry and replication into the host cells. This is followed by different types of nanomaterials which have served as delivery vehicles for the antiviral drugs. It includes various lipid-based, polymer-based, lipid-polymer hybrid-based, carbon-based, inorganic metal-based, surface-modified, and stimuli-sensitive nanomaterials and their application in antiviral therapeutics. The authors also highlight newer promising treatment approaches like nanotraps, nanorobots, nanobubbles, nanofibers, nanodiamonds, nanovaccines, and mathematical modeling for the future. The paper has been updated with the recent developments in nanotechnology-based approaches in view of the ongoing pandemic of COVID-19.

show abstract

Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model

Cited by 42 publications

References 72 publications

Chitosan Derivatives and Their Application in Biomedicine

Chitosan Derivatives and Their Application in Biomedicine

Nanoparticle-Based Vaccines Against Respiratory Viruses

Nanotechnology-based antiviral therapeutics

Contact Info

Product

Resources

About